IRadimed IRMD
Valuation
Multiples measured against the stock's own five-year history
Above its usual level · 69th percentile, 5-year average 43.2x
#2520 of 2991 stocks by PE (1 = cheapest)
Above its usual level · 79th percentile, 5-year average 8.5x
#4946 of 5329 stocks by PB (1 = cheapest)
Above its usual level · 71st percentile, 5-year average 10.6x
#4576 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 10.25 | – | 8.54 | 79% (pricier than usual) | #4946 of 5329 (1 = cheapest) |
| PE | 45.64 | 38.16 | 43.22 | 69% (pricier than usual) | #2520 of 2991 (1 = cheapest) |
| PS | 12.22 | 10.69 | 10.64 | 71% (pricier than usual) | #4576 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on IRMD.
Sign in to join the discussion.